The Effect of Hindbrain Orexin A Signaling on Brown Adipose Tissue Thermogenesis and Physical Activity by Lee, Rachel
  
 
 
The Effect of Hindbrain Orexin A Signaling on Brown Adipose Tissue 
Thermogenesis and Physical Activity 
 
 
Rachel Lee 
 
 
 
Submitted under the supervision of Joshua Nixon, Ph.D., and Tammy Butterick, Ph.D. 
to the University Honors Program at the University of Minnesota-Twin Cities in partial 
fulfillment of the requirements for the degree of Bachelor of Arts summa cum laude in 
Physiology. 
 
 
 
 
09 May 2014
Acknowledgements 
Thank you to my advisors, Drs. Joshua Nixon and Tammy Butterick, for your continued 
support, patience and guidance, and for always pushing me to expand my limits. 
Thank you to Cayla Duffy, my graduate student mentor, for your help in the laboratory, 
assistance with experiments, and willingness to always answer questions. 
Thank you to Joseph Ghilardi and Martha Grace for training me on some of the various 
techniques used in this experiment. 
Thank you to Dr. Catherine Kotz for giving me the opportunity to work with the MN 
Obesity Neuroscience Lab group and for your contributions as a member of my thesis 
committee. Thank you, as well, to Dr. Alessandro Bartolomucci for your contributions as 
a member of my committee. 
Funding for this project was provided by grants from the Department of Veterans Affairs 
RR&D (to JPN) and BLR&D BX001686 (to TAB). A travel grant was provided from the 
University of Minnesota Office of Undergraduate Research (to REL) to present this 
project at the National Conference of Undergraduate Research in Lexington, KY. 
  
 3 
Abstract 
Obesity (body mass index (BMI) ≥ 30) and overweight (BMI 25 - 29) are major 
health concerns in the United States, with the incidence of obesity affecting nearly one 
third of the US population. Previous work has emphasized the importance of 
neuropeptides (protein neurotransmitters) in the control of behaviors associated with 
ingestion and energy expenditure. The orexins (orexin A and orexin B) are a family of 
neuropeptides important in promoting physical activity, and have also recently been 
shown to increase energy expenditure through effects on thermogenesis, specifically via 
the raphe pallidus (RPa) and dorsomedial hypothalamic nucleus. The aim of this project 
is to explore brain-mediated defense against obesity via control of energy expenditure 
(EE), specifically focusing on thermogenesis as regulated by hindbrain orexin A (OXA) 
signaling. While this pathway has been studied in a model using anesthetized rats, 
similar findings have not yet been duplicated in freely moving animals. Our overall 
hypothesis is that orexin signaling in the RPa modulates energy balance by increasing 
brown adipose tissue (BAT) thermogenesis, thereby increasing EE with limited effects 
on physical activity. Rats received fourth ventricle OXA injections and were monitored 
for 24 h for food intake, activity, and calorimetry data. Results show that OXA 
significantly increased heat production (kCal/h) and ambulatory activity in the first two h 
post-treatment (p = 0.0019, and p = 0.0174, respectively). While ambulatory activity did 
increase post-treatment, this difference is not believed to be large enough to fully 
explain the difference in EE during the first 1-2 h. Despite no significant difference in 
UCP1 expression (a marker of BAT thermogenesis), a lack of difference in food intake 
suggests that BAT (rather than diet-induced) thermogenesis is contributing to the 
difference in EE. BAT thermogenesis is an important component of EE in rodents, and 
has recently been confirmed to increase EE in humans as well. Therefore, data from 
this and ongoing studies may contribute to the development of orexin-based therapies 
to increase energy expenditure and reduce body weight in obese humans. 
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Abbreviations 
4V fourth ventricle 
aCSF artificial cerebrospinal fluid 
ANOVA analysis of variance 
AP anterior/posterior 
ATP adenosine triphosphate 
BAT brown adipose tissue 
BMI body mass index 
DMH dorsomedial hypothalamus 
DV dorsal/ventral 
EE energy expenditure 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
LH lateral hypothalamus 
LM lateral/medial 
NEAT non-exercise activity thermogenesis 
OX1R orexin 1 receptor 
OX2R orexin 2 receptor 
OXA orexin A 
OXB orexin B 
PeF perifornical region 
QMR quantitative magnetic resonance 
RNA ribonucleic acid 
RPa raphe pallidus 
RT-PCR reverse transcription polymerase chain reaction 
SD Sprague-Dawley 
SNS sympathetic nervous system 
UCP1 uncoupling protein 1 
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INTRODUCTION 
Obesity (body mass index (BMI) ≥ 30) and overweight (BMI between 25 and 29) 
are major health concerns in the United States (1). Centers for Disease Control data 
show that the incidence of obesity has greatly increased over the past 20 years and 
now affects nearly one third of the US population (2). Obesity is the result of a long-term 
imbalance between energy intake and energy expenditure. Previous work has 
emphasized the importance of neuropeptides – small protein molecules capable of 
acting as neural transmitters within the brain – in the control of behaviors associated 
with ingestion and energy expenditure. Specifically, the hypothalamic neuropeptide 
orexin has been shown to alter feeding and arousal, and orexin effects on non-exercise 
activity thermogenesis (NEAT) have been implicated in the regulation of energy balance 
and expenditure (3). With the use of a polygenic rat model of obesity, it has been shown 
that obesity-resistant rats have higher endogenous orexin sensitivity and orexin receptor 
levels, and that intra-hypothalamic injection of orexin increases NEAT and reduces 
weight gain (4). 
The orexins (hypocretins) are a family containing two peptides, the 33 amino acid 
orexin A (OXA, hypocretin-1) and the shorter 28 amino acid orexin B (OXB, hypocretin-
2), both derived from a single precursor protein, preproorexin, through proteolytic 
processing (5, 6). In the central nervous system, orexin expression is primarily limited to 
cell bodies in the perifornical region (PeF) and adjacent areas of the lateral 
hypothalamus (LH) (7, 8). The orexins bind to two G-protein coupled receptors, orexin 
receptor 1 and 2 (OX1R and OX2R, respectively). OX2R is nonselective, while OX1R 
shows 30- to 100-fold greater affinity for OXA over OXB (5, 9). Because OXA and OXB 
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are produced in the same neurons and have largely identical distribution in the brain (8), 
and because OXB appears to have similar (but less salient) physiological effects as 
OXA (10, 11), most studies using orexin focus solely on OXA. While orexin neurons 
form a diffuse rather than compact cell group, synaptic connections are present 
between orexin neurons, suggesting that subpopulations of orexin cells might 
coordinate functions using these recurrent collateral connections (12). The total number 
of orexin neurons is fairly small, but axonal projections from these cells extend from the 
LH to many regions of the brain and spinal cord (13-17), and the distribution of these 
neurons and axonal projections is very similar across rodent strains and species (8). 
The overall distribution of orexin fibers in the brain and spinal cord allows this small 
population of neurons to play roles in integrating multiple autonomic and behavioral 
functions, primarily feeding, sleep/wake behavior, and arousal (18). Disruptions or 
deficiencies in orexin signaling have been linked to a number of sleep/wake and 
endocrine disorders in humans and in animal models (19-23), and Nixon and colleagues 
have previously shown that rats with higher orexin signaling are protected against 
obesity (18). 
While prior research on orexin-mediated mechanisms of obesity has largely 
focused on the activity-promoting effect of OXA, recent publications show that in 
addition to effects on food intake and physical activity, orexins can also increase energy 
expenditure through effects on thermogenesis (24-27). Data suggest orexins may 
protect against obesity both by effects on physical activity and via brown adipose tissue 
(BAT) thermogenesis. BAT thermogenesis is an important component of energy 
expenditure (EE) in rodents that has recently been shown to exist in adult humans (28, 
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29), and can significantly affect human energy expenditure (30). Consequently, brown 
adipose tissue may represent one of the most promising physiological targets for 
treatment of obesity (31, 32). Orexin protects against body weight gain by stimulating 
increased EE in part via modulation of BAT thermogenesis (18, 33, 34), and orexin 
deficiency in development causes impaired BAT thermogenesis (27). 
The orexin cell fields in the PeF and DMH (dorsomedial hypothalamus) are two 
of several hypothalamic areas known to promote thermogenesis via projections to BAT 
depots (24, 26, 33). Specifically, orexin fibers from the PeF project to the DMH and 
raphe pallidus (RPa), and orexinergic input stimulates RPa neurons, which in turn 
project to BAT to promote thermogenesis (8, 24, 33). A schematic illustrating these 
pathways can be seen in Fig. 1. 
 
Fig. 1: Pathways of thermogenesis. 
Schematic illustrating pathways and mechanisms of thermogenesis. Orexin from perifornical region (PeF) 
or dorsomedial hypothalamus (DMH) activates raphe pallidus (RPa) and brown adipose tissue (BAT) 
thermogenesis.  
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The raphe pallidus is a brainstem nucleus known to play a critical role in BAT 
thermogenesis, and RPa orexin influences this process. Injection of orexin into the RPa 
was shown to significantly increase BAT thermogenesis in anesthetized rats (24). 
Stimulation of the lateral hypothalamic field also increases thermogenesis, and this 
effect can be blocked by inhibition of either the DMH or RPa (26), indicating that 
interaction between these sites is needed for BAT thermogenesis. Retrograde tracer 
studies using a pseudorabies virus injected into BAT show that the RPa is consistently 
labeled before expression of the virus is seen in the DMH (33, 35), suggesting that the 
RPa is downstream of DMH in the pathway for orexinergic stimulation of BAT 
thermogenesis. OXA injection to the 4V has also been shown to induce c-Fos 
expression in the RPa and parapyramidal nucleus (25), providing a potential indirect 
method of stimulating RPa orexin neurons to promote BAT thermogenesis. 
Brown adipose tissue is physiologically distinct from white adipose tissue (WAT) 
in that it is specialized to dissipate energy as heat via non-shivering thermogenesis. 
Conversely, WAT is used for energy storage. Brown adipocytes contain uncoupling 
protein-1 (UCP1), a mitochondrial uncoupling protein expressed predominantly in BAT, 
which, when activated, releases energy as heat by uncoupling oxidative 
phosphorylation from ATP synthesis (36-38). Therefore, an increase in UCP1 is 
indicative of increased thermogenesis. Activators of BAT thermogenesis include stimuli 
such as cold exposure, thiazolidinediones, natriuretic peptides, thyroid hormone, 
fibroblast growth factor 21, and orexin (37, 39). In addition to brown adipocytes, UCP1-
expressing adipocytes, termed beige or “brite”, have also been shown to develop in 
WAT in response to various stimuli (37). However, while UCP1-positive cells have been 
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identified in several classical WAT tissues, studies have shown that traditional BAT 
depots are still the primary contributors to non-shivering thermogenesis (40, 41). In 
rodents, the primary BAT depot is found in the interscapular region, whereas in adult 
humans, BAT is found mostly in the supraclavicular and paravertebral regions. Due to 
its thermogenic properties, BAT has increasingly become a therapeutic target for 
obesity and related metabolic disorders (42, 43). 
Overall, obesity and associated comorbidities greatly increase the risks of other 
chronic diseases and mortality, thus increasing the long-term costs of medical care and 
reducing longevity (1). This study aims to provide information regarding neural 
mechanisms mediating energy expenditure, specifically through hindbrain orexin 
signaling, and to test whether these mechanisms have the potential to be exploited to 
protect against weight gain. Ultimately, data from this and ongoing studies aim to 
contribute to the development of orexin-based therapies to increase energy expenditure 
and reduce body weight in obese humans. 
HYPOTHESIS  
This experiment will test the hypothesis that orexin signaling in the RPa 
modulates energy balance by increasing BAT thermogenesis in freely moving rats. We 
predict that rats receiving hindbrain-targeted OXA will demonstrate increased total 
energy expenditure and decreased weight gain, with little or no effect on physical 
activity and food intake. Following analysis of intrascapular BAT samples, we expect to 
see increased UCP1 expression, indicating increased BAT thermogenesis. 
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METHODS 
Animals 
Adult male Sprague-Dawley (SD) rats (Charles River, Chicago, IL USA; n = 16) 
were housed in accordance with the National Institutes of Health guidelines in a 
temperature-controlled room (21-22°C) with an alternating 12 h light/12 h dark 
photoperiod  (lights on at 0600 h). Rodent chow (8604, Harlan Teklad, Madison, WI 
USA) and water were allowed ad libitum. All studies were approved by the local 
Institutional Animal Care and Use Committee at the Minneapolis Veterans Affairs Health 
Care System. 
Surgery and Injections 
Rats with surgically implanted unilateral stainless steel guide cannulae (Plastics 
One, Roanoke, VA USA) targeting the fourth ventricle (AP: -12.0; L/M: ±0.0; 
DV: -9.8 mm relative to bregma) were used for this study. A dummy stylet extending to 
the tip of the cannula was placed in the guide cannula following surgery and between 
injections. Animals were allowed at least 1 week of recovery from surgery prior to 
initiation of experiments. 
For several days prior to beginning injections, rats were habituated by gentle 
handling and removal of cannula caps. For injections, rats were gently restrained and 
cannula caps were removed. A stainless steel injector was inserted into the cannula and 
a volume of 0.5 µl was delivered manually over 30 s using a Hamilton syringe attached 
to the injector. Injectors were left in place for an additional 15 s following injectate 
delivery to ensure proper delivery; after injection, the injector was removed and cannula 
caps with dummy stylets were replaced. Animals were then weighed and returned to the 
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cage/monitoring system. Prior to beginning experimental treatments, rats received at 
least 1 d of artificial cerebrospinal fluid (aCSF) injections for acclimation purposes and 
to resolve any potential blockage in the cannulae. 
Food Intake, Body Weight, and Body Composition Measurements 
Food intake (total food removed from hopper minus spillage, in grams) and body 
weight were measured daily during each experiment phase. Spillage was defined as 
any food removed from the hopper but not ingested. Food intake and body weight 
measurements were collected within the same time period (0830-0930 h) on all days, 
unless otherwise indicated. Direct measurement of body composition, including total fat 
and lean mass, was obtained approximately 24 h prior to euthanasia using a 
quantitative magnetic resonance (QMR) body composition analyzer (EchoMRI, Houston, 
TX USA) as described in Nixon et al (44). 
Physical Activity and Energy Expenditure Measurements 
Physical activity was measured using an open-field activity system (Med 
Associates, St. Albans, VT USA). Rodents were individually placed in chambers 
equipped with an array of infrared beams to monitor physical activity, defined as time 
ambulatory (beam breaks in x and y axes). Time spent vertical (beam breaks in z axis) 
was also recorded during Experiment 2 and reported together with ambulatory time as 
time spent moving. Energy expenditure was determined by thermogenesis calculated 
from O2 consumption and CO2 production measured in individual-chamber indirect 
calorimeters (CLAMS, Columbus Instruments, Columbus, OH USA). Both a standard 
CLAMS set-up (using 7 ⅜” x 12 ⅛” x 6 ¾” acrylic chambers) and a large set-up (using 
17” x 17” x 6 ¾” acrylic chambers) were used. The standard test chambers were used 
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to allow for greater accuracy in indirect calorimetry measurements, while the large test 
chambers were used to attempt to differentiate between EE resulting from NEAT and 
EE resulting from BAT thermogenesis. Both systems were customized to incorporate 
the Med Associates open-field activity beam array, allowing for simultaneous collection 
of physical activity and indirect calorimetry data. For all experiments, animals were 
allowed 3 d of acclimation to the test chambers prior to data collection. Data was 
collected every 30 s and analyzed in 1 h bins. During the first acclimation period, one 
animal become ill and had to be removed from the study. Animals were given access to 
food and water ad libitum while in the chambers. 
Collection of Brain and Adipose Tissue 
Upon conclusion of the study, ink was injected into the cannula to aide in 
placement verification, and rats were euthanized by decapitation. Brains were removed 
and stored in 10% buffered formalin. Intrascapular BAT depots were collected, minced, 
and divided into samples of ≤ 250 mg. Samples were then flash frozen in liquid nitrogen. 
Verification of Cannula Placement 
Cannula placement was verified by the presence of cerebrospinal fluid at the 
injection site and/or using histological evaluation. Brains were sectioned at 40 µm onto 
glass slides using a cryostat. Slides were examined under a light microscope, and the 
anatomical location of the end of the cannula tract was identified with the aid of a rat 
brain atlas (45). Only rats with correctly placed cannulas (within a 1 mm diffusion 
distance of the fourth ventricle) were included in the analysis (Fig. 2, OXA: n = 7, aCSF: 
n = 7). 
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Fig. 2: Verification of cannula placement.  
Cannula placement as verified using histological evaluation. Coordinates from Paxinos & Watson (45), 
relative to bregma. 
Gene and Protein Expression Analysis 
RNA was isolated from BAT and WAT samples using the RNeasy Micro Kit 
(Qiagen) for column-based isolation. Tissue samples were homogenized prior to RNA 
isolation with the aid of TRIzol (Invitrogen) and a Bullet Blender (Next Advance, BBX24). 
UCP1 expression, normalized to GAPDH and tissue weight, was tested using qRT-PCR, 
with samples run at a concentration of approximately 50 ng/µl, measured using a 
NanoDrop 8000 spectrophotometer (Thermo Scientific). Samples were prepared using 
the LightCycler RNA Amplification Kit: SYBR Green I (Roche) and 10 µM primer mix, 
and qRT-PCR was run using the Roche LightCycler Carousel-Based System 
-11.04mm
-11.52mm
-11.64mm
-12.00mm
-11.04 to - 12.00 mm
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(LightCycler 1.5). Primer sequences were generated using MacVector 12 and 
commercially obtained from Integrated DNA Technologies. The sequences of the 
primers used were as follows: GAPDH, accession number NM_017008, forward 5’-GAC 
ATC AAG AAG GTG GTG AAG CAG-3’, reverse 5’-AAG GTG GAA GAA TGG GAG 
TTG C-3’; UCP1, accession number NM_012682, forward 5’-TGG CAT CCA GAG GCA 
AAT CAG-3’, reverse 5’-AGC ATT GTA GGT CCC AGT GTA GCG-3’. The primers 
were previously verified to generate the PCR product of interest using gel 
electrophoresis following PCR reaction and products were sequenced using the Sanger 
di-deoxy chain terminator method (University of Minnesota Genomic Center, St. Paul, 
MN USA). 
 Mitochondria were isolated from BAT samples using a commercially available kit 
(Pierce Thermo Scientific) as described by the manufacturer’s provided protocol and in 
(46). Briefly, tissue was homogenized while on ice with a Dounce homogenizer, in the 
presence of protease inhibitors. Subsequent homogenization was completed using the 
kit’s provided buffers, and the resulting pellet was suspended in RIPA buffer (Pierce 
Thermo Scientific). Protein content was determined using a Bradford assay (BioRad). 
Mitochondrial fractions (7.5 µg) were mixed in SDS-loading buffer and separated on 10% 
polyacrylamide gels (BioRad). Membranes were incubated in primary antibody (UCP1, 
Santa Cruz, sc-6795) following incubation in blocking buffer (Superblocker, Pierce 
Thermo Scientific) at a final dilution of 1:1000 using the SNAP i.d. system (Millipore) as 
described in (47). Secondary antibodies were used at a final concentration of 1:60,000 
(rabbit anti-goat IgG HRP, Abcam, ab97100). Detection was determined following 
addition of the HRP substrate (West Pico-Super Signal, Pierce Thermo Scientific) by 
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placing membranes on x-ray film and developing using an Agfa Developer CP1000 
(Agfa Corporation). Density of bands was determined using Image Studio software (LI-
COR Biosciences). The mitochondrial inner membrane protein prohibitin was used as a 
loading control as it is constitutively expressed in mitochondrial fractions and would not 
be present in a cytosolic fraction. 
Experimental Design 
Rats were singly housed in standard hanging wire rodent caging except when 
undergoing activity or calorimetry measurements. A single cohort of rats was used for 
all experiments, with rats randomly assigned to OXA or aCSF treatment groups 
following baseline measurements. Baseline body weight and 24 h food intake measures 
were taken for three days prior to beginning the experiments, and rats were randomly 
assigned treatments such that these measures did not differ between groups. 
Experimental groups were maintained across all studies, with the exception of one 
animal that was switched from the aCSF to OXA group following Experiment 2 in order 
to keep groups even after several animals had to be excluded from the study due to an 
equipment error. 
Experiment 1: Rats were placed in standard test chambers, treated with vehicle 
(aCSF), and allowed to acclimate for 72 h. On the 4th day, rats received aCSF (0.5 µl, 
n = 7) or OXA (300 pmol/0.5 µl, n = 8) between 0900 and 0930 h. Indirect calorimetry 
and physical activity (time ambulatory) was then measured for 24 h, with data collection 
starting at 1000 h. 
Experiment 2: Rats were placed in the large test chambers, treated with vehicle, 
and allowed to acclimate for 72 h. On the 4th day, rats received aCSF (n = 7) or OXA 
 17 
(n = 8) between 0900 and 0930 h. Indirect calorimetry and physical activity (time 
ambulatory and time spent vertical) was then measured for 24 h, with data collection 
starting at 1000 h. Due to equipment error, data from 4 animals (3 OXA-treated, 1 
aCSF-treated) had to be excluded from the study following the 1 h time point. 
Experiment 3: Rats were kept in their standard home cages and treated with 
either OXA (n = 6) or vehicle (n = 5) between 0900 and 0930 h. Food intake was 
measured 1 h following injection, and again 24 h following injection. 
Experiment 4: Approximately 24 h prior to euthanasia, body composition data for 
each animal was obtained. The following day, rats received treatment with either OXA 
(n = 6) or aCSF (n = 5). Injections were done every 10 min, with two animals per time 
point, from approximately 0930 to 1020 h. At 90 min post-injection, rats were euthanized, 
and brain and adipose tissue samples were collected. Brains were used to verify 
cannula placement, while BAT samples were tested for UCP1 expression following RNA 
isolation. 
Statistics 
Statistical analyses were performed and data were graphically represented using 
GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA USA). Timecourse data from all 
experiments were analyzed using repeated measures two-way ANOVA, followed by 
Bonferroni post-tests. Calorimetry and food intake data were analyzed using unpaired 
two-tailed t tests. Real-time RT-PCR data were analyzed for relative changes in gene 
expression using the Δ-ΔCT method (48) and unpaired two-tailed t tests. Western blot 
data was analyzed using Image Studio (LI-COR Biosciences) software and unpaired 
two-tailed t tests.  
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 RESULTS  
 Experiment 1: Injection of OXA into the 4V significantly increased energy 
expenditure in the first two h following treatment (Fig. 3A, p = 0.0019). Data show that 
OXA treatment did not significantly affect 24 h energy expenditure (Fig. 3B), total 
energy expenditure during the light or dark periods, or food intake. However, when 
energy expenditure was examined hourly, a significant interaction (treatment x time) 
was observed (Fig. 4, p < 0.0001). Specifically, orexin-treated animals had significantly 
higher energy expenditure at 1000 h and decreased energy expenditure throughout the 
dark period (with this difference being significant at 0300 h), when compared to controls. 
Examination of ambulatory time revealed a significant interaction (treatment x time) for 
both cumulative (p = 0.0374) and non-cumulative (p = 0.0048) data (Fig. 5). Time spent 
moving was significantly increased for treated animals at 1000 h, and significantly 
 
Fig. 3: Effect of orexin A (OXA) on thermogenesis (kCal). 
(A) OXA (300 pmol/0.5 µl) significantly increased energy expenditure in the first 2 h following 
treatment (p = 0.0019). (B) OXA did not alter 24 h energy expenditure. 
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 Fig. 4: Effect of orexin A (OXA) on hourly energy expenditure (kCal/h). 
Significant interaction (treatment x time, p < 0.0001) was found in hourly energy expenditure 
(EE). OXA significantly increased EE in the first 1 h (p < 0.001) and significantly decreased EE 
at 0300 h (p < 0.01). 
 
 
Fig. 5: Effect of orexin A (OXA) on ambulatory time (min). 
Significant interaction (treatment x time, p = 0.0373) was observed in ambulatory data. OXA 
significantly increased ambulatory time in first 1 h post-treatment (p < 0.01) and decreased 
ambulation at 0300 h (p < 0.05) 
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Fig. 6: Effect of orexin A (OXA) on thermogenesis (kCal) in large test chambers. 
 (A) Animals treated with OXA (300 pmol/0.5 µl) in large test chambers had slightly increased 
energy expenditure (EE) in the first 1 h following treatment compared to controls; however, this 
difference was not significant (p = 0.1738). (B) OXA did not alter 24 h EE. 
 
 
Fig. 7: Effect of orexin A (OXA) on hourly energy expenditure (kCal/h) in large chambers. 
Significant interaction (treatment x time, p < 0.0001) was found in hourly energy expenditure 
(EE) for animals treated in the large test chambers. OXA significantly decreased EE at 0300 h 
(p < 0.05). 
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decreased at 0300 h, compared to controls. A significant effect of treatment on 
ambulatory time was also observed in orexin-treated animals during the first two h 
following treatment (p = 0.0174). 
 Experiment 2: Data show that OXA injection into the 4V increased energy 
expenditure and ambulatory activity in the first h following treatment. While these data 
follow the same trends as those seen in Experiment 1, the changes observed in this 
experiment were not significant (Figs. 6-8). No difference was observed in 24 h 
cumulative ambulatory time, total energy expenditure, hourly ambulatory time, time 
spent moving (ambulatory plus vertical, cumulative and non-cumulative), or food intake 
for treated versus control animals. Again, a significant interaction (treatment x time) was 
observed in the hourly energy expenditure data (p = 0.0003), with orexin-treated rats 
having significantly lower energy expenditure at 0300 h compared to controls (p < 0.05).  
 Experiment 3: In an attempt to explain the observed increase in energy 
expenditure and ambulatory activity in orexin-treated animals in the first 1-2 h following 
injection, food intake was measured 1 and 24 h following treatment with OXA or vehicle. 
The data show no significant difference in food intake between orexin- or aCSF-treated 
animals at either 1 or 24 h following injection (Fig. 9A). While food intake appears to be 
slightly higher in orexin-treated animals 1 h following injection, at 24 h post-injection, 
food intake is equal among groups, if not slightly higher in animals treated with vehicle. 
 Experiment 4: Prior to euthanasia and tissue collection, body composition from 
all animals was obtained. Data show no difference in fat mass between treated and 
control animals, though treated animals had slightly, but significantly, less lean 
 
Fig. 8: Effect of orexin A (OXA) on hourly physical activity (min) in large test chambers. 
No significant interaction (treatment x time) was observed in either (A) ambulatory time (p = 
0.0806) or (B) time spent moving (ambulatory + vertical, p = 0.1029) for animals in the large test 
chambers. 
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 Fig. 9: Effect of orexin A (OXA) on food intake (g) and body composition (g). 
(A) No significant difference in food intake was observed. (B) Fat mass did not differ between 
OXA and control animals, though OXA animals had slightly but significantly less lean mass than 
controls (p = 0.0463). 
 
  
Fig. 10: Efffect of orexin A (OXA) on uncoupling protein-1 (UCP1) protein and mRNA expression. 
While there was a trend for increased BAT UCP1 protein expression (left) and mRNA 
expression (right) in OXA-treated animals, this difference was not significant. 
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mass than controls (Fig. 9B, p = 0.0463). This, however, is believed to be a result of 
difference in baseline body composition. An analysis of UCP1 mRNA expression in BAT 
showed that while UCP1 expression was slightly higher in orexin-treated animals, this 
difference was not significant. Protein levels of UCP1 expression were also examined 
via Western blot. Data show that UCP1 expression, normalized to prohibitin, was not 
significantly different between treatment groups (Fig. 10). 
DISCUSSION  
The goal of this study was to provide information regarding neural mechanisms 
mediating energy expenditure via hindbrain OXA signaling, and to test whether these 
mechanisms might ultimately have the potential to be exploited to protect against weight 
gain. A previous study showed that injection of orexin A into the rostral RPa of 
anesthetized rats significantly increased BAT thermogenesis (24). To determine 
whether these findings could be duplicated in freely moving animals, a series of 
experiments was performed in which rats were injected into the 4V with either OXA or 
vehicle (aCSF) and monitored for feeding, activity, and indirect calorimetry. The same 
experiment was done in standard test chambers (to allow for greater accuracy in 
indirect calorimetry measurements) and large test chambers (to attempt to differentiate 
between EE resulting from NEAT and EE resulting from BAT thermogenesis). At the 
end of the experiments and following a final injection, intrascapular brown adipose 
tissue was collected and used for analysis of gene and protein expression. Ultimately, 
OXA treatment was shown to increase energy expenditure in the first 1-2 h following 
treatment, with this difference being significant when the animals were tested in the 
standard test chambers. Data from gene and protein expression analyses, however, 
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showed no significant change in UCP1 expression, as would be expected with an 
increase in BAT thermogenesis (49).  
The significant increase in energy expenditure observed in treated animals in the 
first 1-2 h following treatment in Experiment 1 suggests increased SNS-induced BAT 
activation and a possible increase in BAT thermogenesis. While ambulatory activity also 
increased post-treatment, the observed difference (1 min versus 30 s over 1 h) does not 
appear large enough to fully explain the difference in EE in the first h. Furthermore, if an 
increase in ambulatory activity were the sole reason for increased EE in the first 2 h 
post-treatment, we would expect to also observe a significant increase in ambulatory 
activity in OXA-treated rats in Experiment 2, when the rats were given greater room for 
activity. This, however, was not the case; no change in time spent moving or time 
ambulatory was observed between treatment groups in Experiment 2 (Appendix 3). 
Although the significant increase in EE in the first h post-treatment was not observed 
when the large test chambers were used (despite being present in Experiment 1), this is 
not unusual, considering that indirect calorimetry measurements are less sensitive in 
the larger chambers. 
Despite these arguments, as an increase in ambulatory activity (significant in 
Experiment 1, non-significant in Experiment 2) was observed alongside the initial 
increase in EE, it was necessary to determine whether BAT thermogenesis or an 
alternative source of thermogenesis – such as a thermic effect of food – was 
responsible for the increase in energy expenditure. As the orexins are known to 
stimulate feeding and activity when administered centrally to areas such as the lateral 
hypothalamus or paraventricular hypothalamic nucleus (3-6), food intake was monitored 
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at both 1 h and 24 h post-treatment to see if an increase in feeding may have caused 
the increases in EE and SPA (spontaneous physical activity). At 1 h post treatment, 
although OXA-treated animals appeared to have eaten slightly more than their 
untreated counterparts, there was no significant difference in food intake between the 
treatment groups. After 24 h, OXA animals appeared to have eaten slightly less than the 
vehicle group, though, again, this difference was not significant. These results suggest 
that the observed increases in EE in the first 1-2 h post-treatment cannot be solely 
attributed to feeding and feeding-related activity, but that another source of energy 
expenditure – such as BAT thermogenesis – is also playing a role. 
Injection of OXA into the hindbrain also appears to elicit a possible rebound 
effect on energy expenditure during the dark phase. These findings appear to be in line 
with data from other orexin studies (18, 50) in which a rebound effect was also observed. 
In both Experiments 1 and 2, OXA significantly decreased EE at 0300 h (p < 0.05), and 
overall EE during the dark phase is dampened. While Experiment 1 also showed a 
significant decrease in ambulatory activity at 0300 h (p < 0.05), based on overall activity 
data from Experiments 1 and 2, this appears to be simply a random fluctuation. 
Essentially, OXA-treated animals are overcompensating during the dark phase for their 
increased energy expenditure early on, due to the short-acting effects of OXA, though 
the reasoning for this remains unclear. Further exploration into this phenomenon would 
be necessary to understand the exact mechanisms involved and to determine whether 
the rebound effect can be prevented in order to maintain an overall increase in EE (and 
thus a net weight decrease) for OXA-treated animals. To do so would require looking at 
downstream targets of orexin or other orexin agonists and seeing if the effects seen 
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here could be duplicated. Based on current literature, possible targets could include 
glutamate or melanin-concentrating hormone (39, 49). An alternative approach could 
utilize subchronic administration of orexin via osmotic minipump, as this method, 
combined with biotelemetry probes to monitor BAT, has been shown to produce 
profound changes in BAT thermogenesis (49). The hindbrain is an important area for 
this research as it acts as a site of neural integration for signals to brown adipose tissue 
coming from other areas of the brain including the hypothalamus and brainstem nuclei 
such as the preoptic area, arcuate hypothalamic nucleus, paraventricular hypothalamic 
nucleus, periaqueductal gray matter, DMH, and RPa (51, 52). 
While there was a trend for increased BAT UCP1 expression in OXA-treated 
animals from both PCR and Western blot data (Fig. 7), this difference was not 
significant, as would be expected if the increase in EE were a result of BAT 
thermogenesis (36). It should be noted that one of the control/aCSF samples was not 
included in analysis of the Western blot data as a loading or transfer error seems to 
have occurred, and not enough sample was present to perform a densitometry analysis. 
One possible explanation for the observed data is that the hindbrain OXA signaling was 
not strong enough to elicit a significant increase in UCP1. This theory would be 
consistent with data showing that OXA-induced increases in BAT thermogenesis require 
an ongoing, basal level of BAT sympathetic nerve activity which would not have been 
present in the warm (i.e. room temperature and unaltered body/skin temperature) 
conditions used (24). While OXA injection to the 4V has also been shown to induce 
neuronal activation in the RPa, 4V OXA administration is not a direct method of 
stimulating RPa orexin neurons and has been shown to activate OXA neurons in other 
 28 
areas, including the parapyramidal nucleus, that are involved in the modulation of 
cardiovascular and gastrointestinal functions in addition to brown fat thermogenesis (25). 
Thus, it is possible that direct targeting of the RPa may be necessary for OXA 
stimulation of BAT thermogenesis. While direct cannulation of the RPa may have 
resulted in a more robust increase in thermogenesis and UCP1 expression, the decision 
to target the RPa indirectly stemmed from concern over cannulating an area in such 
close proximity to brainstem centers responsible for basic cardiovascular and 
respiratory functions. The indirect method, using 4V administration of OXA, offers a 
safer and more clinically feasible approach for the study of orexin-based therapies. 
Overall, data from this study suggests that hindbrain OXA signaling has the 
potential to increase EE via BAT thermogenesis, though perhaps not without also 
increasing ambulatory activity. It also appears that direct cannulation of the RPa may be 
necessary for more salient effects of OXA on BAT thermogenesis and UCP1 expression 
to be seen.  While no effect of OXA treatment on body weight was observed, when body 
composition was analyzed by QMR, it was noted that OXA treated animals did have 
slightly, yet significantly, less lean mass than control animals (p = 0.0463). This is 
believed to be a result of baseline difference in the treatment groups, and not an effect 
of treatment itself. Therefore, it would be advised to perform a body composition 
assessment pre- and post- treatment in future experiments. Similarly, as baseline EE 
and activity measurements were not taken, it is possible that differences observed 
between treated and control groups may have been pre-existing; however, because 
both groups were matched by weight and food intake, this is an unlikely possibility. 
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Future directions would include repeating the experiment described here with 
more animals, comprehensive baseline measurements, and direct cannulation of the 
RPa. As poor yield from isolation of BAT mitochondria was an issue, a larger n would 
allow for treatment groups to be divided and BAT samples to be analyzed by either 
qPCR or Western blot, rather than performing both analyses on a single BAT depot. 
Future experiments may also involve looking at the effects of OXA signaling in the PeF 
and DMH on BAT thermogenesis and UCP1 expression, as these areas are also known 
to promote thermogenesis via projections to BAT depots (24, 26, 33) but evidence of 
this in freely moving animals is lacking. Evidence of this nature is particularly important 
in obesity research, as while volitional exercise is one of the first recommended actions 
for individuals aiming to lose weight, we are an increasingly sedentary society and many 
obese individuals suffer from limited mobility. In addition to volitional activity, NEAT and 
other alternative forms of energy expenditure have been shown to have significant 
potential for increasing weight loss (53, 54). Ultimately, data from these and ongoing 
studies aim to contribute to the development of orexin-based therapies with the potential 
to increase EE and reduce body weight in obese humans. 
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